207 related articles for article (PubMed ID: 21535368)
21. Governmental influences on drug development: striking a better balance.
Miller HI; Henderson DR
Nat Rev Drug Discov; 2007 Jul; 6(7):532-9. PubMed ID: 17491596
[TBL] [Abstract][Full Text] [Related]
22. The trouble with drink and drugs: why prohibition and criminalization matter.
Levine HG; Reinarman C
Addiction; 2010 May; 105(5):806-7. PubMed ID: 20402973
[No Abstract] [Full Text] [Related]
23. Tobacco, public health, and the FDA.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2009 Jul; 361(4):402-3. PubMed ID: 19546344
[No Abstract] [Full Text] [Related]
24. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970.
Tobbell DA
Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387
[TBL] [Abstract][Full Text] [Related]
25. Bioequivalence: the regulatory career of a pharmaceutical concept.
Carpenter D; Tobbell DA
Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
[TBL] [Abstract][Full Text] [Related]
26. The costs of compliance.
Leeman E
J Am Acad Psychoanal Dyn Psychiatry; 2007; 35(2):179-87. PubMed ID: 17650971
[TBL] [Abstract][Full Text] [Related]
27. Antibiotics, big business, and consumers. The context of government investigations into the postwar American drug industry.
Bud R
Technol Cult; 2005 Apr; 46(2):329-49. PubMed ID: 16116706
[No Abstract] [Full Text] [Related]
28. Shattuck lecture. Innovation, regulation, and the FDA.
Hamburg MA
N Engl J Med; 2010 Dec; 363(23):2228-32. PubMed ID: 21121835
[No Abstract] [Full Text] [Related]
29. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
Watson KT; Barash PG
Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
[TBL] [Abstract][Full Text] [Related]
30. Not as easy as it may appear: using radio frequency identification technology to fulfill the Prescription Drug Marketing Act's elusive pedigree requirement.
Asamoah AK
Food Drug Law J; 2006; 61(2):385-418. PubMed ID: 16903035
[No Abstract] [Full Text] [Related]
31. Teaching clinicians about drugs--50 years later, whose job is it?
Avorn J
N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
[No Abstract] [Full Text] [Related]
32. Drug regulation and policy formulation.
Nightingale SL
Milbank Mem Fund Q Health Soc; 1981; 59(3):412-44. PubMed ID: 7024847
[TBL] [Abstract][Full Text] [Related]
33. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
34. Drugs, the criminal law, and the administration of justice.
Moore MH
Milbank Q; 1991; 69(4):529-60. PubMed ID: 1806801
[TBL] [Abstract][Full Text] [Related]
35. The 1941 sulfathiazole disaster and the birth of good manufacturing practices.
Swann JP
Pharm Hist; 1999; 41(1):16-25. PubMed ID: 11623769
[No Abstract] [Full Text] [Related]
36. RU-486: legal and policy issues confronting the Food and Drug Administration.
Muhl C
J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
[TBL] [Abstract][Full Text] [Related]
37. An alternative perspective: homeopathic drugs, Royal Copeland, and federal drug regulation.
Junod SW
Food Drug Law J; 2000; 55(1):161-83. PubMed ID: 12375600
[No Abstract] [Full Text] [Related]
38. The goose that laid the golden capsule, part I.
Smith BE
Tenn Med; 2005 May; 98(5):224-5. PubMed ID: 15934531
[No Abstract] [Full Text] [Related]
39. Alternative drugs: homeopathy, Royal Copeland, and federal drug regulation.
White Junod S
Pharm Hist; 2000; 42(1-2):13-35. PubMed ID: 11624552
[No Abstract] [Full Text] [Related]
40. Two centuries of assessing drug risks.
Avorn J
N Engl J Med; 2012 Jul; 367(3):193-7. PubMed ID: 22808954
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
